The EU Court of Justice will consider whether the EU General Court erred in affirming ECHA decisions that require Symrise to conduct new animal testing to assess the reproductive and other health effects of UV filters homosalate and octisalate. In recent failed bids for interim relief, Symrise argued that the animal testing is likely to cause “irreparable damage” to its interests.
Symrise AG is asking the EU’s highest court to annul two European Chemicals Agency Board of Appeal decisions requiring the supplier to test UV filters on animals in order to satisfy information needs under the Registration, Evaluation, Authorization and Restriction of Chemicals regulation.
The cases concern homosalate (T-656/20) and 2-ethylhexyl salicylate, aka octisalate (T-655-20) – both permitted UV filters under the...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
